Multiple Myeloma in 2023 Ways: From Trials to Real Life

Curr Oncol. 2023 Nov 3;30(11):9710-9733. doi: 10.3390/curroncol30110705.


Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse. Basic research has made giant strides in better characterizing the molecular mechanisms of the disease. The results have led to the manufacturing of new, revolutionary drugs which have been widely tested in clinical trials. These drugs have been approved and are now part of the therapeutic armamentarium. As a consequence, it is essential to combine what we know from clinical trials with real-world data in order to improve therapeutic strategies. Starting with this premise, our review aims to describe the currently employed regimens in multiple myeloma and compare clinical trials with real-life experiences. We also intend to put a spotlight on promising therapies such as T-cell engagers and chimeric antigen receptor T-cells (CAR-T) which are proving to be effective in changing the course of advanced-stage disease.

Keywords: CAR-T cells therapy; autologous stem cell transplantation; bispecific antigens; daratumumab; frailty; minimal residual disease; multiple myeloma; real-life; relapsed-refractory disease; sequencing; standard of care.

Publication types

  • Review

MeSH terms

  • Hematologic Neoplasms*
  • Humans
  • Multiple Myeloma* / drug therapy
  • Neoplasm Recurrence, Local
  • T-Lymphocytes

Grants and funding

This research received no funding.